Capricor Therapeutics (CAPR) Tops Q3 EPS by 7c

Capricor Therapeutics (NASDAQ: CAPR) reported Q3 EPS of ($0.12), $0.07 better than the analyst estimate of ($0.19).

For earnings history and earnings-related data on Capricor Therapeutics (CAPR) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Ennis (EBF) Reports In-Line Q1 EPS
• Primoris cuts 2026 outlook on renewables cost overruns, COO exits